An Update on the Use of Immunotherapy in the Treatment of Lymphoma
Purpose of Review
Throughout the field of oncology, immunotherapy is moving further towards the first-line setting, and there is encouraging data for the use of these novel therapies in the management of lymphomas, utilizing treatments approved for both solid and hematologic malignancies. Herein, we review promising advances in this rapidly moving field from the past year.
In the last year, we have seen promising clinical data on engineered antibody therapies for the treatment of lymphomas, as well as further optimization of engineered antibody fragments fused onto linkers or chimeric T cell receptors, both of the modalities capable of transforming non-specific T cells into tumor-specific, serial killer cells.
Here we will review the promising data on these advances in antibody-based therapies, as well as some of the immunomodulators and checkpoint-blocking therapies that shown to have promising results in the treatment of lymphomas within the past year.
Compliance with Ethical Standards
Conflict of Interest
Thomas U Marron, Matko Kalac, and Joshua Brody each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article contains no studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Gyan E, et al. Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 LyMa Trial of the Lysa/Goelams Group. Blood. 2016;128(22):145.Google Scholar
- 4.Vitolo U, Trněný M, Belada D, Carella AM, Chua N, Abrisqueta P, et al. Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final results from an open-label, randomized phase 3 study (GOYA). Blood. 2016;128(22):470.Google Scholar
- 5.•• Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10. The randomized phase 3, CLL11 trial substantiated nearly 20 years of research since the 1997 approval of rituximab to result in the first clinically significant improvement in anti-CD20 antibody therapy, demonstrating a PFS improvement with obinutuzumab versus rituximab (and an OS improvement versus no antibody). Later follow-up demonstrated the OS benefit versus rituximab coming closer towards significance (0.11 in this study, 0.09 in subsequent follow-up). Thus study should inspire continued research into optimization of antibody effector function across different molecular targets, lymphoid and otherwise. CrossRefPubMedGoogle Scholar
- 6.Marcus RE, Davies AJ, Ando K, Klapper W, Opat S, Owen CJ, et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM study. Blood. 2016;128(22):6.Google Scholar
- 8.Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol. 1997;15(4):1567–74.CrossRefPubMedGoogle Scholar
- 11.Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, et al. Single-agent MOR208 in relapsed or refractory (R-R) non-Hodgkin's lymphoma (NHL): results from diffuse large B-cell lymphoma (DLBCL) and indolent NHL subgroups of a phase IIa study. Blood. 2016;128(22):623.Google Scholar
- 12.Woyach JA, Ruppert AS, Awan FT, Jones J, Andritsos LA, Waymer S, et al. Updated results from a phase II study of the fc engineered CD19 antibody MOR208 in combination with lenalidomide for patients with chronic lymphocytic leukemia (CLL) and Richter’s transformation or Ibrutinib for patients with Ibrutinib-resistant clones. Blood. 2016;128(22):4386.Google Scholar
- 13.Budde LE, Halwani A, Yasenchak CA, Farber CM, Burke JM, Fayad LE, et al. Results of an ongoing phase 2 study of brentuximab vedotin with Rchp as frontline therapy in patients with high-intermediate/high-risk diffuse large B cell lymphoma (DLBCL). Blood. 2016;128(22):104.Google Scholar
- 14.Kim YH, Whittaker S, Horwitz SM, Duvic M, Dummer R, Scarisbrick JJ, et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician’s choice (methotrexate or bexarotene): the phase 3 Alcanza study. Blood. 2016;128(22):182.Google Scholar
- 16.• Phillips T, Brunvand M, Chen A, Press O, Essell J, Chiappella A, et al. Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib/II study. Blood. 2016;128(22):622. This single patient case report is acknowledged in a high impact journal because of the slow therapeutic advancement in T cell (as compared to B cell) NHL and paucity of ongoing clinical trials for novel agents in these diseases. Subsequent to this publication, a Phase 2 trial assessing the agent in relapsed NK/T lymphoma has been initiated (NCT02927925). Of note, a proportion of both AITL and PTCL-NOS also express moderate to high levels of CD38. Google Scholar
- 17.Phillips A, Fields P, Hermine O, Ramos JC, Beltran BE, Pereira J, et al. A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab versus investigator’s choice in the treatment of patients with relapsed/refractory adult T-cell leukemia-lymphoma: overall response rate, progression-free survival, and overall survival. Blood. 2016;128(22):4159.Google Scholar
- 20.Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34(10):1104–11.CrossRefPubMedGoogle Scholar
- 21.• Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–6. The largest study to date assessing the efficacy of bi-specific antibody therapy in a disease other than ALL, demonstrating 43%ORR and 19%CR, comparing favorably with other novel agents in this group of relapsed DLBCL patients. Clinical trials combining bi-specifics with checkpoint blockade are ongoing. CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Bannerji R, Brown JR, Advani RH, Arnason J, O’Brien SM, Allan JN, et al. Phase 1 study of REGN1979, an anti-CD20 x anti-CD3 Bispecific monoclonal antibody, in patients with CD20+ B-cell malignancies previously treated with CD20-directed antibody therapy. Blood. 2016;128(22):621.Google Scholar
- 27.Khouri IF, Curbelo IF, Turturro F, Milton DR, Kim RA, Jabbour EJ, et al. Lenalidomide with ipilimumab for lymphoid malignancies after allogeneic or autologous stem cell transplantation (SCT). Blood. 2016;128(22):1164.Google Scholar
- 30.•• Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9. This seminal study both set a new standard of care for salvage therapy in Hodgkin’s Lymphoma -resulting in the agent’s FDA approval- and demonstrated amongst the highest response rates for checkpoint blockade immunotherapy in any malignancy. CrossRefPubMedGoogle Scholar
- 31.Armand P, Shipp MA, Ribrag V, Michot J-M, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733-9. doi: 10.1200/jco.2016.67.3467.
- 32.Diefenbach CS, Hong F, David KA, Cohen J, Robertson M, Advani R, et al. Title: a phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412 arms D and E). Blood. 2016;128(22):1106.Google Scholar
- 35.Zinzani PL, Ribrag V, Moskowitz CH, Michot J-M, Kuruvilla J, Balakumaran A, et al. Phase 1b study of pembrolizumab in patients with relapsed/refractory primary mediastinal large b-cell lymphoma: results from the ongoing Keynote-013 trial. Blood. 2016;128(22):619.Google Scholar
- 36.Khodadoust M, Rook AH, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, et al. Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a citn multicenter phase 2 study. Blood. 2016;128(22):181.Google Scholar
- 38.• Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35. This study is the first to bring one of the newer, ‘targeted’ agents approved for MCL salvage therapy into an up-front, chemo-free regimen, with impressive response rates even comparing favorably with recent up-front MCL trials of R-Bendamustine or R-CHOP (e.g. BRIGHT study). The high frequency of ATM and p53 mutations in MCL suggests that immunotherapy-based therapies might avoid selection of -or induction of- aggressive, chemo-resistant sub-clones. CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16(9):1245–56.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–102.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9.CrossRefPubMedGoogle Scholar
- 45.Schuster SJ, Svoboda J, Nasta SD, Chong EA, Winchell N, Landsburg DJ, et al. Treatment with chimeric antigen receptor modified T cells directed against CD19 (CTL019) results in durable remissions in patients with relapsed or refractory diffuse large B cell lymphomas of germinal center and non-germinal center origin, “double hit” diffuse large B cell lymphomas, and transformed follicular to diffuse large B cell lymphomas. Blood. 2016;128(22):3026.Google Scholar
- 46.Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Miklos D, Jacobson CA, et al. Abstract CT019: primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Cancer Research. 2017;77(13 Supplement): CT019-CT. doi: 10.1158/1538-7445.am2017-ct019.
- 47.Crump M, Neelapu SS, Farooq U, Neste EVD, Kuruvilla J, Ahmed MA, et al. Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. J Clin Oncol. 2016;34(15_suppl):7516-. doi: 10.1200/JCO.2016.34.15_suppl.7516.
- 48.Gomes da Silva D, Mukherjee M, Srinivasan M, Dakhova O, Liu H, Grilley B, et al. Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with B-cell lymphoma: reversal of toxicity from tonic signaling. Blood. 2016;128(22):1851.Google Scholar
- 50.Brudno JN, Shi V, Stroncek D, Pittaluga S, Kanakry JA, Curtis LM, et al. T cells expressing a novel fully-human anti-CD19 chimeric antigen receptor induce remissions of advanced lymphoma in a first-in-humans clinical trial. Blood. 2016;128(22):999.Google Scholar
- 54.Shah NN, Stetler-Stevenson M, Yuan CM, Shalabi H, Yates B, Delbrook C, et al. Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood. 2016;128(22):650.Google Scholar
- 55.•• Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–44. This abstract describes the seminal dataset from the ZUMA-1 study which was used for the registration of ‘axicel’ an immunotherapy milestone, apparently the first FDA-approved CAR-T product and an important model and proof-of-principle for subsequent approvals. CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Bhardwaj N, Merad M, Kim-Schulze S, Crowley B, Davis T, Salazar A, et al. Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585]. J Immunother Cancer. 2014;2(Suppl 3):45.CrossRefGoogle Scholar
- 62.Marron T, Bhardwaj N, Crowley E, Keler T, Davis TA, Brody J. Turning a tumor into a vaccine factory: in situ vaccination for low-grade lymphoma. Blood. 2014;124(21):5473-5473.Google Scholar
- 63.Flowers C, Isufi I, Herrera A, Okada C, Cull E, Kis B, et al. Intratumoral G100 induces systemic immune responses and abscopal tumor regression in patients with follicular lymphoma [abstract]. J Clin Oncol Off J Am Soc Clin Oncol. 2017; Abstract 7537.Google Scholar